The double-edged sword of Notch signaling in cancer

Seminars in Cell and Developmental Biology

Volumn 23, Issue 4, 2012, Pages 458-464

  South, Andrew P ^a   Cho, Raymond J ^b   Aster, Jon C ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Notch signaling; Oncogene; Tumor suppressor

Indexed keywords

NOTCH RECEPTOR; NOTCH1 RECEPTOR; ONCOPROTEIN;

B CELL LEUKEMIA; BREAST CARCINOMA; CANCER GENETICS; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; NONHUMAN; ONCOGENE; PATHOGENESIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84861987137     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.01.017     Document Type: Review

References (48)

1. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137(April (2)):216-233.
2. Aster J.C., Pear W.S., Blacklow S.C. Notch signaling in leukemia. Annu Rev Pathol 2008, 3:587-613.
3. Radtke F., Fasnacht N., Macdonald H.R. Notch signaling in the immune system. Immunity 2010, 32(January (1)):14-27.
4. Pui J.C., Allman D., Xu L., DeRocco S., Karnell F.G., Bakkour S., et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999, 11(September (3)):299-308.
5. Zweidler-McKay P.A., He Y., Xu L., Rodriguez C.G., Karnell F.G., Carpenter A.C., et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005, 106(December (12)):3898-3906.
6. Saito T., Chiba S., Ichikawa M., Kunisato A., Asai T., Shimizu K., et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003, 18(May (5)):675-685.
7. Thomas M., Calamito M., Srivastava B., Maillard I., Pear W.S., Allman D. Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood 2007, 109(April (8)):3342-3350.
8. Santos M.A., Sarmento L.M., Rebelo M., Doce A.A., Maillard I., Dumortier A., et al. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc Natl Acad Sci U S A 2007, 104(September (39)):15454-15459.
9. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194(December (11)):1625-1638.
10. Di Ianni M., Baldoni S., Rosati E., Ciurnelli R., Cavalli L., Martelli M.F., et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol 2009, 146(September (6)):689-691.
11. Sportoletti P., Baldoni S., Cavalli L., Del Papa B., Bonifacio E., Ciurnelli R., et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010, 151(November (4)):404-406.
12. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475(July (7354)):101-105.
13. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011, 208(July (7)):1389-1401.
14. Rasi S., Monti S., Spina V., Foa R., Gaidano G., Rossi D. Analysis of NOTCH1 mutations in monoclonal B cell lymphocytosis. Haematologica 2011, (October).
15. Del Giudice I., Rossi D., Chiaretti S., Marinelli M., Tavolaro S., Gabrielli S., et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2011, (December).
16. Balatti V., Bottoni A., Palamarchuk A., Alder H., Rassenti L.Z., Kipps T.J., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2011, (November).
17. Wang L., Lawrence M.S., Wan Y., Stojanov P., Sougnez C., Stevenson K., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011, 365(December (26)):2497-2506.
18. Kridel R., Meissner B., Rogic S., Boyle M., Telenius A., Woolcock B., et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2011, [e-published December 30].
19. Leshchenko V.V., Kuo P.Y., Shaknovich R., Yang D.T., Gellen T., Petrich A., et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010, 116(August (7)):1025-1034.
20. Lee S.Y., Kumano K., Nakazaki K., Sanada M., Matsumoto A., Yamamoto G., et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009, 100(May (5)):920-926.
21. Zhao B., Zou J.Y., Wang H., Johannsen E., Peng C-W., Quackenbush J., et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A 2011, 108:14902-14907.
22. Rosenwald A., Wright G., Wiestner A., Chan W.C., Connors J.M., Campo E., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3(February (2)):185-197.
23. Robbins J., Blondel B.J., Gallahan D., Callahan R. Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J Virol 1992, 66(April (4)):2594-2599.
24. Klinakis A., Szabolcs M., Politi K., Kiaris H., Artavanis-Tsakonas S., Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 2006, 103(June (24)):9262-9267.
25. Kakarala M., Wicha M.S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008, 26(June (17)):2813-2820.
26. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70(January (2)):709-718.
27. Mazzone M., Selfors L.M., Albeck J., Overholtzer M., Sale S., Carroll D.L., et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 2010, 107(March (11)):5012-5017.
28. Robinson D.R., Kalyana-Sundaram S., Wu Y.M., Shankar S., Cao X., Ateeq B., et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 2011, 17(12):1646-1651.
29. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33(March (3)):416-421.
30. Proweller A., Tu L., Lepore J.J., Cheng L., Lu M.M., Seykora J., et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res 2006, 66(August (15)):7438-7444.
31. Lefort K., Mandinova A., Ostano P., Kolev V., Calpini V., Kolfschoten I., et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 2007, 21(March (5)):562-577.
32. Rangarajan A., Talora C., Okuyama R., Nicolas M., Mammucari C., Oh H., et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001, 20(July (13)):3427-3436.
33. Restivo G., Nguyen B.C., Dziunycz P., Ristorcelli E., Ryan R.J., Ozuysal O.Y., et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J 2011, (September).
34. Demehri S., Turkoz A., Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009, 16(July (1)):55-66.
35. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333(August (6046)):1157-1160.
36. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333(August (6046)):1154-1157.
37. Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 2011, 108(October (43)):17761-17766.
38. Cordle J., Redfieldz C., Stacey M., van der Merwe P.A., Willis A.C., Champion B.R., et al. Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity. J Biol Chem 2008, 283(April (17)):11785-11793.
39. Westhoff B., Colaluca I.N., D'Ario G., Donzelli M., Tosoni D., Volorio S., et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A 2009, 106(December (52)):22293-22298.
40. Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473(May (7346)):230-233.
41. Yan M., Callahan C.A., Beyer J.C., Allamneni K.P., Zhang G., Ridgway J.B., et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463(February (7282)):E6-E7.
42. Liu Z., Turkoz A., Jackson E.N., Corbo J.C., Engelbach J.A., Garbow J.R., et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 2011, 121(February (2)):800-808.
43. Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(October (5694)):269-271.
44. Breit S., Stanulla M., Flohr T., Schrappe M., Ludwig W.D., Tolle G., et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006, 108(August (4)):1151-1157.
45. van Grotel M., Meijerink J.P., van Wering E.R., Langerak A.W., Beverloo H.B., Buijs-Gladdines J.G., et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008, 22(January (1)):124-131.
46. Asnafi V., Buzyn A., Le Noir S., Baleydier F., Simon A., Beldjord K., et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113(April (17)):3918-3924.
47. Lin Y.W., Nichols R.A., Letterio J.J., Aplan P.D. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2006, 107(March (6)):2540-2543.
48. O'Neil J., Calvo J., McKenna K., Krishnamoorthy V., Aster J.C., Bassing C.H., et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006, 107(January (2)):781-785.